Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
March 6, 2019
CytoSorbents to Present at the Cowen 39th Annual Health Care Conference
MONMOUTH JUNCTION, N.J., March 6, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in ...
March 6, 2019
miRagen Therapeutics to Present a Corporate Overview at the 29th Annual Oppenheimer & Co. Healthcare Conference
BOULDER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, ...
March 6, 2019
Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
SYDNEY, Australia, March 06, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments ...
March 6, 2019
Immutep doses First Patient in TACTI-002 Phase II Trial
SYDNEY, Australia, March 06, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), announces the first patient has been dosed ...
March 6, 2019
Urovant Sciences Appoints James Robinson to its Board of Directors
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)-- Urovant Sciences (UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced ...
March 6, 2019
Krystal Biotech Continues Vertical Integration with Official Inauguration of Ancoris Gene Therapy Manufacturing Facility at its Pittsburgh Headquarters
PITTSBURGH, March 06, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases, announced today official ...
March 6, 2019
Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
March 6, 2019
Foamix Pharmaceuticals to Present at the Cowen & Company 39th Annual Health Care Conference
REHOVOT, Israel and BRIDGEWATER, N.J., March 06, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing ...
March 6, 2019
Lipocine Announces Financial and Operational Results for the Year Ended December 31, 2018
SALT LAKE CITY, March 6, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced financial results for the year ended December 31, 2018. ...
March 6, 2019
CymaBay Announces Pricing of Public Offering of Common Stock
NEWARK, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies ...
March 6, 2019
Genocea to Present at the Cowen & Company 39th Annual Health Care Conference
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president ...
March 6, 2019
Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019
ROCHESTER, N.Y., March 06, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat ...
March 6, 2019
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2018 Financial Results and Provide Business Update on Wednesday, March 13
TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of ...
March 6, 2019
INVENTIVA to Present Corporate Overview at the Cowen and Company 39th Annual Health Care Conference
Daix (France), March 6, 2019 - Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas ...
March 6, 2019
Bionano Genomics to Present at the Cowen and Company 39th Annual Health Care Conference
SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ...
March 6, 2019
PolarityTE to Present at the 39th Annual Cowen Healthcare Conference and at the 13th Annual Canaccord Genuity Musculoskeletal Conference
SALT LAKE CITY, March 6, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) announced today that it will attend and present at the Cowen 39th Annual Healthcare Conference ...
March 6, 2019
Pfenex Licensee Successfully Completes a Phase 3 Study and Enters Registration for Pneumosil®
SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (SIIPL), has completed ...
March 6, 2019
OncoCyte Corporation to Present at Cowen and Company 39th Annual Health Care Conference in Boston
ALAMEDA, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, ...
March 6, 2019
Aptevo Announces Proposed Public Offering of Common Stock and Warrants
SEATTLE, March 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced ...
February 26, 2019
Neovasc Announces Pricing of $5 Million Public Offering of Common Shares
VANCOUVER, Feb. 26, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today the pricing of its previously announced underwritten ...
Page 39 of 169